<DOC>
	<DOCNO>NCT01732224</DOCNO>
	<brief_summary>The relevant data prospectively collect included patient demographic , clinical , laboratory variable include virological test , genotyping direct sequencing , abdominal ultrasound , upper gastrointestinal ( GI ) endoscopy . Trans jugular liver biopsy ( TJLB ) hepatic venous pressure gradient ( HVPG ) do patient evident whether underlie liver disease chronic base clinical , biochemical , radiological investigation , upper GI endoscopy . Severity liver disease assess Child-Turcotte Pugh score ( CTP ) model end stage liver disease ( MELD ) score .</brief_summary>
	<brief_title>To Compare Efficacy Combined Tenofovir Plus Telbivudine v Tenofovir Alone Patients With Spontaneous Reactivation Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Reactivation CHB characterize rise ALT level &gt; 5 time upper limit normal along HBV DNA level &gt; 10^5 copies/ mL ( &gt; 1.8 X 10^4 IU/mL ) . 1 . Superinfection virus ( hepatitis E , A , D , C ) 2. cause chronic liver failure 3. coexistent hepatocellular carcinoma ( HCC ) 4. portal vein thrombosis 5. coexistent renal impairment 6. pregnancy 7. coinfection human immunodeficiency virus ( HIV ) 8. patient receive previous course antiviral , immunomodulator cytotoxic/immunosuppressive therapy chronic hepatitis illness within least precede 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>